Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
-
BUSINESS Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
-
BUSINESS JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
-
BUSINESS US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
-
BUSINESS Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
-
BUSINESS Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
-
BUSINESS Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
-
BUSINESS Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
-
REGULATORY CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
January 31, 2012
-
REGULATORY JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal
January 30, 2012
-
ORGANIZATION JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
January 27, 2012
-
REGULATORY Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness
January 26, 2012
-
REGULATORY 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion
January 25, 2012
-
BUSINESS Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
-
BUSINESS Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
-
REGULATORY PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis
January 20, 2012
-
BUSINESS Takeda President Hasegawa Envisions Japanese National as Successor
January 19, 2012
-
BUSINESS Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
-
ORGANIZATION JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
-
REGULATORY US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…